Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Hepatic Resection Slows Progression of Carcinoid Heart Disease

By HospiMedica staff writers
Posted on 18 Mar 2008
Resection of hepatic carcinoid metastases is associated with a decreased risk of progression of carcinoid heart lesions and with improved survival and prognosis, claims a new study.

Researchers at The Mayo Clinic (Rochester, MN, USA) analyzed the effect of hepatic resection on progression of cardiac lesions and prognosis in 77 patients with carcinoid heart disease who had serial echocardiograms done at least one year apart. More...
Ten of these patients had resections performed during the observation period.

The study results showed that progression of cardiac lesions was seen in one of the ten patients (10%) who underwent hepatic resection during follow-up, compared with 42 of 67 patients (63%) who did not undergo hepatic resection during that period. Patients who had no resection also had a significantly greater increase in echocardiographic (ECG) score and significantly higher 5-hydroxyindoleacetic acid (5-HIAA)--a breakdown product of the chemical messenger serotonin--levels than did patients who underwent hepatic resection. Five-year survival after carcinoid heart disease diagnosis was significantly greater in patients who had hepatic resection (86.5%, versus 29.0% in patients without hepatic resection). The study was published in the February 2008 issue of Mayo Clinic Proceedings.

"Our findings suggest that, in patients with carcinoid heart disease who are eligible for hepatic resection, surgical debulking of the tumor burden in the liver can improve survival,” concluded lead author Alain M. Bernheim, M.D., and colleagues. "Eligible patients with metastatic carcinoid tumors and carcinoid heart disease should be considered for hepatic surgery before their tumors have reached an inoperable state.”

Carcinoid heart disease--a slow-growing but malignant type of tumor originating in the cells of the neuroendocrine system-- is associated with liver metastases that permit large quantities of vasoactive substances to reach the right side of the heart without being inactivated by the damaged first-pass liver metabolism.


Related Links:
The Mayo Clinic

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.